{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:50:58Z","timestamp":1791996658343,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jbo.2026.100789","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:09:54Z","timestamp":1784934594000},"page":"100789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-resorptive agents in neuroendocrine bone metastases \u2013 A systematic review"],"prefix":"10.1016","volume":"60","author":[{"given":"Marianne S.","family":"Elston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Chan Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade A.U.","family":"Tamatea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2026.100789_bb0005","doi-asserted-by":"crossref","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u2018carcinoid\u2019: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008\/06\/21. 2008;26:3063\u201372. doi:https:\/\/doi.org\/10.1200\/JCO.2007.15.4377.","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"10.1016\/j.jbo.2026.100789_bb0010","doi-asserted-by":"crossref","unstructured":"Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology 2017\/02\/06. 2018;106:30\u20137. doi:https:\/\/doi.org\/10.1159\/000457954.","DOI":"10.1159\/000457954"},{"key":"10.1016\/j.jbo.2026.100789_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102168","article-title":"Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: a systematic review and meta-analysis","volume":"94","author":"Garcia-Torralba","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2026.100789_bb0020","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0147","article-title":"Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study","volume":"32","author":"Lavezzi","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jbo.2026.100789_bb0025","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1055\/a-2159-5548","article-title":"Bone metastases in patients with pancreatic NETs: prevalence and prognosis","volume":"55","author":"Mathew","year":"2023","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.jbo.2026.100789_bb0030","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ejrad.2015.06.024","article-title":"Clinical value of 68Ga-DOTATATE-PET\/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET)","volume":"84","author":"Albanus","year":"2015","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.jbo.2026.100789_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70115","article-title":"Bone metastases from neuroendocrine neoplasms: results of an Italian nationwide survey of natural history and management","volume":"38","author":"Fazio","year":"2026","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.jbo.2026.100789_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EC-14-0119","article-title":"Bone metastases and skeletal-related events from neuroendocrine tumors","volume":"4","author":"Van Loon","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.jbo.2026.100789_bb0045","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of Zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate Cancer","volume":"96","author":"Saad","year":"2004","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2026.100789_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2026.100789_bb0055","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2026.100789_bb0060","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2026.100789_bb0065","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100789_bb0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-024-01046-2","article-title":"In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease","volume":"14","author":"Lund","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jbo.2026.100789_bb0075","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12020-019-01838-8","article-title":"The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice","volume":"64","author":"Alexandraki","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.jbo.2026.100789_bb0080","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jbo.2026.100789_bb0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","article-title":"A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research","volume":"35","author":"Muka","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.jbo.2026.100789_bb0090","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer's Manual [Internet]. The Joanna Briggs Institute; 2017. Available from: https:\/\/reviewersmanual.joannabriggs.org\/."},{"key":"10.1016\/j.jbo.2026.100789_bb0095","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2017.35.15_suppl.4096","article-title":"Use of antiresorptive therapy (ART) and skeletal-related events (SREs) in patients with bone metastases of neuroendocrine neoplasms (NEN)","author":"Apostolidis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100789_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106710","article-title":"Symptomatic spinal metastases from neuroendocrine neoplasms: surgical outcomes and prognostic analysis","volume":"207","author":"Leng","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jbo.2026.100789_bb0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers authors bone metastasis: mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jbo.2026.100789_bb0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2026.100789_bb0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbo.2017.09.003","article-title":"The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials","volume":"9","author":"Zhang","year":"2017","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2026.100789_bb0120","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.clinthera.2020.05.019","article-title":"Denosumab versus zoledronic acid in the prevention of skeletal-related events in vulnerable cancer patients: a meta-analysis of randomized, controlled trials","volume":"42","author":"Chen","year":"2020","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jbo.2026.100789_bb0125","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","article-title":"Cost-effectiveness analysis of monthly Zoledronic acid, Zoledronic acid every 3 months, and monthly Denosumab in women with breast Cancer and skeletal metastases: CALGB 70604 (Alliance)","volume":"35","author":"Shapiro","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2026.100789_bb0130","first-page":"2341","article-title":"Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis","volume":"30","author":"Ikesue","year":"2022","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jbo.2026.100789_bb0135","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jbo.2026.100789_bb0140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137426000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:30:31Z","timestamp":1791995431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137426000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S2212137426000515"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100789","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-resorptive agents in neuroendocrine bone metastases \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2026.100789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100789"}}